Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Manfred Wuhrer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0814-4995; OpenAlex author ID A5065397150. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases. Co-author DOI 10.1097/mpa.0000000000002517↗
  2. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Co-author DOI 10.1038/s42003-024-06087-8↗
  3. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. Co-author DOI 10.1136/jitc-2023-007805↗
  4. Transforming growth factor-β challenge alters the N-, O-, and glycosphingolipid glycomes in PaTu-S pancreatic adenocarcinoma cells. Co-author DOI 10.1016/j.jbc.2022.101717↗
  5. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
  6. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  7. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Co-author DOI 10.3390/ijms22052655↗
  8. Serum N-Glycome analysis reveals pancreatic cancer disease signatures. Co-author DOI 10.1002/cam4.3439↗
  9. Differential O- and Glycosphingolipid Glycosylation in Human Pancreatic Adenocarcinoma Cells With Opposite Morphology and Metastatic Behavior. Co-author DOI 10.3389/fonc.2020.00732↗
  10. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. Last author DOI 10.1038/s41598-017-16811-6↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuri E. M. van der Burgt · 4 shared papers, 2020–2025 · strength 0.59
  2. Wilma E. Mesker · 4 shared papers, 2020–2025 · strength 0.59
  3. Monique Esther van Leerdam · 3 shared papers, 2021–2025 · strength 0.49
  4. Yvette van Kooyk · 3 shared papers, 2022–2024 · strength 0.42
  5. Kelly Boelaars · 3 shared papers, 2022–2024 · strength 0.42
  6. Ernesto Rodríguez · 3 shared papers, 2022–2024 · strength 0.42
  7. Elisa Giovannetti · 3 shared papers, 2017–2024 · strength 0.36
  8. Randa G. Hanna-Sawires · 3 shared papers, 2020–2022 · strength 0.36
  9. Bert A. Bonsing · 3 shared papers, 2020–2022 · strength 0.36
  10. Rob A.E.M. Tollenaar · 3 shared papers, 2020–2022 · strength 0.36
  11. Derk C.F. Klatte · 2 shared papers, 2022–2025 · strength 0.35
  12. Jing Zhang · 2 shared papers, 2020–2022 · strength 0.28
  13. Peter ten Dijke · 2 shared papers, 2020–2022 · strength 0.28
  14. Tao Zhang · 2 shared papers, 2020–2022 · strength 0.28
  15. Maarten F. Bijlsma · 2 shared papers, 2022–2024 · strength 0.27
  16. Hans F. A. Vasen · 2 shared papers, 2021–2022 · strength 0.26
  17. Stephanie Holst · 2 shared papers, 2017–2022 · strength 0.25
  18. Aleksander M. Bogdanski · 1 shared paper, 2025 · strength 0.23
  19. Jeanin Elise van Hooft · 1 shared paper, 2025 · strength 0.23
  20. Michael B. Wallace · 1 shared paper, 2025 · strength 0.23
  21. Yan Bi · 1 shared paper, 2025 · strength 0.23
  22. Gerda C. M. Vreeker · 2 shared papers, 2020–2022 · strength 0.22
  23. Ana I. Belo · 2 shared papers, 2017–2020 · strength 0.20
  24. Irma van Die · 2 shared papers, 2017–2020 · strength 0.20
  25. Chang Liu · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.